Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LuCa-MERIT-1: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Next Previous
X
Search
Trial Profile

LuCa-MERIT-1: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BNT 116 (Primary) ; Carboplatin (Primary) ; Cemiplimab (Primary) ; Docetaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man
  • Acronyms LuCa-MERIT-1
  • Sponsors BioNTech

    • Most Recent Events

    • 11 Mar 2024 According to a BioNTech media release, preliminary results of this study will be presented at the American Association for Cancer Research Annual Meeting 2024 in San Diego, California, from April 5-10, 2024
    • 04 Oct 2023 Planned number of patients changed from 80 to 130.
    • 04 Oct 2023 Planned End Date changed from 1 Jul 2027 to 1 Aug 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top